Alpha Cognition's ZUNVEYL, FDA-approved in July 2024, targets Alzheimer's with improved tolerability over existing galantamine therapies. ZUNVEYL's pricing is competitive versus newer Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback